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Abstract 
 
Aim: The aim of this study was to assess the economic performance of the application of the 
policy for negotiating discounts on drug products and agreements on the controlled access of 
patients in Bulgaria.  
Methods: The methodology involves comparison of the amounts of public spending on 
medicines in two periods – during the course of the analyzed drug policies (January 2007 – 
June 2009), and the period in which negotiations on the price of medicines and programs for 
the controlled access of the patients was discontinued (July 2009 – December 2012).  
Results: In Bulgaria, the government did not apply methods for controlling public 
expenditure on medicines bargaining price concessions from manufacturers and 
implementing agreements on controlled access of patients after June 2009. This led to an 
annual increase in the expenditures on drug products for home treatment (on average, 17% 
for the period 2009-2012). 
Conclusion: This trend in Bulgaria will continue in the future since expenditure control only 
through price control by means of a reference system and the positive list of medicines is 
ineffective. There is a need for implementation of combined drug policies in Bulgaria in the 
form of negotiations on rebates with manufacturers and agreements on controlled access of 
patients and reference pricing. 
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Introduction 
The contemporary approaches to drug policy in a number of European Union (EU) countries 
include negotiating discounts and rebates between the health insurance funds and the 
pharmaceutical manufacturers, as well as agreements for risk sharing in order to reduce the 
impact of the new patented medicines on the public budget. 
Negotiating some form of discount between the manufacturers and the funds has different 
forms and ways of administration in different countries and, in some cases, pharmacies give 
up part of their statutory surcharges (e.g. the Netherlands) (1). In other cases, they impose 
administrative requirements for discounts on the pharmaceutical manufacturers (Germany, 
Spain, Portugal) (2), whereas in further cases manufacturers recover part of the cost of the 
reimbursed medicines when the previously agreed annual limits are exceeded (France) (3). 
Such policies of paying back are becoming more and more popular and are currently being 
applied in at least ten EU countries. 
Until June 2009, the National Health Insurance Fund (NHIF) in Bulgaria negotiated discounts 
with manufacturers on the prices of patented medicines and administratively determined the 
conditions of pharmacies for their dispensing. For these products, pharmacists were not 
allowed to charge the statutory determined retail surcharge and received a minimum fixed fee 
for the dispensing of medicines. Subsequently, in June 2009, with the adoption of a Positive 
Drug List (PDL), the possibility of NHIF to negotiate prices and discounts on medicines were 
legally discontinued. 
The agreements for sharing the financial risk and the controlled access of patients to 
treatment with proprietary medicinal products are also a tool for the management and control 
of public spending. The need for such agreements highlights the rapidly growing share of 
drug costs for the treatment of certain diseases such as cancer, viral infections, neurological 
diseases, or diabetes and the increasing concern of the governments about the relatively high 
level of health consumption of new drugs compared to the standard therapeutic alternatives. 
In the EU countries, there exist several different schemes for financial risk sharing: 
• Agreements of the type “price-quantity”. These are purely financial schemes that lead 
to recovery when there is an excess in the previously agreed schemes by the 
producers’ sales. 
• Agreements of the type “controlled access for the patients”. They are based on an 
approach that the medicines are provided free-of-charge or at a lower price by the 
manufacturer for a limited period in order to facilitate financing (4). 
• Agreements based on the results. They are based on the recovery of the costs, if a 
previously agreed upon level of therapeutic results is not reached, e.g. the desired 
improvement of health. 
Ultimately, no matter what the specific approach will be, the agreements for risk sharing 
reduce the risk of overspending the budget of the public health insurance fund. They are 
particularly useful for restricting the use of drugs by those segments of the population which 
generate the least benefits (5). 
In the Bulgarian health system, agreements for the controlled access of patients were applied 
until June 2009 in the form of health programs for expensive treatment of socially significant 
diseases such as diabetes, chronic renal failure, hepatitis, multiple sclerosis, schizophrenia, 
bipolar disorder, or Parkinson’s disease. Access to these health programs was granted for 
patients who met specific criteria for the disease and diagnostic indicators, confirmed by 
special medical commissions. These health programs for the controlled access of patients 
have been discontinued since June 2009 and the access was extended to all patients with 
these diagnoses. 
As a modern political tool that limits the impact on public spending, especially for innovative 
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drugs of uncertain benefit, the agreements for sharing the financial risk are an interesting and 
promising approach. At present, however, there is no systematic evaluation of their 
application and results achieved in Bulgaria.  
In this context, the aim of the current study was to assess the economic results of the 
implementation of the policies for negotiating discounts and medical products and the 
agreements on the controlled access of patients in Bulgaria. The study questions included a 
comparative analysis of the cost of the expenses for drug products throughout two periods, in 
which different practices for their regulation were employed – in the first period there were 
employed policies of negotiating the prices, internal reference pricing and programs for 
regulated access to patients, while in the next period only policies for external and internal 
reference pricing were used. The tested hypothesis was that the complex policy of reference 
pricing, negotiating prices and programs for a controlled access contribute to the success of a 
more effective regulation of the drug products costs, in comparison to the separate 
employment of policies for external and internal reference pricing.  
 
Methods 
The methodology consisted of comparing the value of public spending on medicines in two 
periods – during the course of the analyzed drug policies (January 2007 – June 2009) (6) and 
the period when negotiating the price of medicines and the programs for the controlled access 
of patients was discontinued (July 2009 – December 2012) (7). 
The official data for the expenses of NHIF for reimbursing the medicinal products were used 
for the current analysis. We compared the quantities and the value of the medicinal products, 
which have been completely reimbursed and were used for the treatment of multiple 
sclerosis, hepatitis, schizophrenia and diabetes. These expenses constitute 25% of the costs 
for the completely reimbursed medicinal products. At the beginning of the period under 
consideration (2007), medicines had patent protection and there were no registered generic 
products in the market. Up to 2009, public expenses of these medicinal products were 
controlled through a complex of measures which included agreements for sharing the 
financial risk and policies of price discounts.  
 
Results 
The public expenditure on NHIF medicines for the period of 2007-2012 are presented in 
Figure 1. The costs up to June 2009 are presented in two parts – partially reimbursed 
medicines and completely free medicines, which are controlled by negotiating discounts, an 
administrative reduction of the surplus charge of pharmacies and programs to control patient 
access to the expensive treatment of certain socially significant diseases. After June 2009, all 
the NHIF approaches employed to control costs were terminated, and the cost of public funds 
for medicines were operated only by the PDL, based on external and internal reference 
pricing. 
The data analysis shows that during the period 2007-2009 (when discount policies and 
agreements on the controlled access were applied), the cost of medicines for three years 
increased from 282 million BGN to 325 million BGN, i.e. an increase of 15%. For a similar 
period (2010-2012), when the public spending was controlled only by external and internal 
reference pricing, the cost of medicines increased from 366 million BGN to 524 million BGN 
(up to 43%). Therefore, it is reasonable to conclude that the long-term results of drug policies 
on discounts and programs for the controlled access of patients are more effective in terms of 
public spending, than the independent application of a reference price system within the PDL. 
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Figure 1. Public expenditure on NHIF medicines for the period 2007-2012  
(Source: Statement of the cash execution of the NHIF budget) 
 
 
 
Table 1 displays the quantitative analysis of the most commonly used medicines for the 
treatment of multiple sclerosis, hepatitis, schizophrenia and diabetes, which in 2008 were 
dispensed under the programs for controlled access that were discontinued after June 2009. 
After the termination of the agreements for controlled access, the reimbursed amounts of the 
NHIF drug products increased between 14% (Insulin human) and 157% (Peginterferon) by 
2012 compared to 2008.  
 
Table 1. The amount of annual sales during the period 2008-2012  
(Source: IMS Health, 2008-2012) 
 
Medicine 2008 (number) 
2009 
(number) 
2010 
(number) 
2011 
(number) 
2012 
(number) 
Interferon β 12,277 15,863 19,364 21,175 25,741 
Peginterferon 14,087 18,285 35,435 34,731 36,244 
Olanzapinе 62,650 70,145 64,002 71,958 105,744 
Aripiprazole 24,224 26,799 35,265 39,147 41,429 
Insulin human 4,527,237 4,783,584 4, 854, 414 5,082,538 5,166,258 
 
Table 2 displays an analysis of the values that were reimbursed by the NHIF for the same 
products. Public spending on the examined medicinal products increased between 16% 
(Insulin human) and 118% (Peginterferon) by 2012. An exception is the reimbursed expense 
for Olanzapine. The main reason is the expiry of the patent protection and the registration of 
generic medicines. 
 
Table 2. The value of annual sales during the period of 2008-2012  
(Source: IMS Health, 2008-2012) 
 
Medicine 2008, BGN 2009, BGN 2010, BGN 2011, BGN 2012, BGN 
Interferon β 9,717,166 12,585,278 16,392,076 16,207,345 18,495,318 
Peginterferon 5,571,752 6,563,072 12,485,396 12,293,382 12,166,795 
Olanzapinе 11,871,082 11,319,137 9,592,246 8,795,552 7,686,233 
Aripiprazole 5,178,861 4,883,137 5,713,810 6,376,297 6,711,932 
Insulin human 44,209,976 45,246,122 44,617,054 49,667,806 51,433,736 
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Discussion  
The increased public spending after 2009 once again demonstrates that the combination of 
various drug policies like negotiating discounts with manufacturers, agreements for the 
controlled access of patients and reference pricing are much more effective for the 
management and control of costs, than the administration of external and internal reference 
pricing by a PDL. The complex approach is the only possibility for price control of the 
innovative medicinal products (Interferon, Peginterferon, Insulin, Aripiprazole), where there 
are no generic alternatives and the internal reference pricing approach cannot be applied. 
Moreover, the pharmaceutical companies have control over the external reference pricing to a 
large degree and prefer to register their innovative products first at the high price markets in 
the EU (8). In these situations, the small pharmaceutical markets, such as the Bulgarian 
market, are threatened by a delayed access to the contemporary drug therapies. There is a 
high probability that analogical cases would occur in all countries in Southeast Europe and it 
is recommended that complex drug policies are applied for the management of the public 
costs on medicinal products.  
The general rationale of the integrated approach to the drug policy is to accelerate the patient 
access towards innovative medicines, while ensuring that the financial risks are shared on the 
basis of estimated or actual cost-effectiveness and the impact of the consumption of 
medicines on the public budget. 
The decrease in the cost of the product Olanzapine by 35% in 2012 compared to 2008, 
confirms the effectiveness of the approach for generic substitution, which regulates public 
spending without compromising the therapeutic goals. By 2015, according to the data from 
IMS Health, over 60% of the patent-protected drugs as of 2012 will be available as generics 
(9,10). The expiration of patent protection will make a large segment of the market available 
for generic medicines, and this will create a huge potential for saving financial resources. In 
addition, generics are just as good for health as original drugs are (11). 
 
Conclusion 
After June 2009, the government of Bulgaria did not apply methods to control the public 
expenditure of drug products, such as negotiating price discounts from manufacturers and the 
implementation of agreements for the controlled access to patients. This led to an annual 
increase in the expenditure of NHIF for medicines for home treatment by an average of 17% 
for the period 2009-2012. This trend will continue in the future because the cost control only 
through price controls by the reference system and the PDL is ineffective. It is necessary to 
implement a combination of policies on medicines, like negotiating discounts with the 
manufacturers, agreements for the controlled access of patients and reference pricing (12,13). 
The contemporary drug policies presume that there is an increase in the role of pharmaco-
economic evaluation when making decisions for the reimbursement of the medicinal products 
and the management of public expenses (14). The countries of Southeast Europe are still 
beginners in this process, but the fast creation of academic structures for economic evaluation 
of the medicinal therapies, which help the decision making committees on reimbursement, 
will improve the future efficacy of the complex drug policies for control of public expenses 
on medicinal products (15).  
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